Literature DB >> 12097416

Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.

Caishu Deng1, Elzbieta Goluszko, Erdem Tüzün, Huan Yang, Premkumar Christadoss.   

Abstract

To provide direct genetic evidence for a role of IL-6 in experimental autoimmune myasthenia gravis (EAMG), IL-6 gene KO (IL-6(-/-)) mice in the C57BL/6 background were immunized with Torpedo californica acetylcholine receptor (AChR) and evaluated for EAMG. Only 25% of AChR-immunized IL-6(-/-) mice developed clinical EAMG compared to 83% of C57BL/6 (wild-type) mice. A significant reduction in the secondary anti-AChR Ab of IgG, IgG(2b), and IgG(2c), but not the primary or secondary IgM response was observed in AChR-immunized IL-6(-/-) mice, suggesting a possible defect in T cell help and class switching to anti-AChR IgG(2) isotype. The AChR-specific lymphocyte proliferative response, IFN-gamma, and IL-10 production were suppressed in AChR-immunized IL-6(-/-) mice. EAMG resistance in IL-6(-/-) mice was associated with a significant reduction in germinal center formation and decreased serum complement C3 levels. The data provide the first direct genetic evidence for a key role of IL-6 in the autoimmune response to AChR and in EAMG pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097416     DOI: 10.4049/jimmunol.169.2.1077

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

3.  Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells.

Authors:  Minchan Gil; Seo-Jeong Park; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 4.  Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function.

Authors:  Christopher D C Allen; Jason G Cyster
Journal:  Semin Immunol       Date:  2008-02-07       Impact factor: 11.130

5.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

6.  Experimental autoimmune myasthenia gravis in the mouse.

Authors:  B Wu; E Goluszko; P Christadoss
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 7.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

8.  Elevated serum level of interleukin-32α in the patients with myasthenia gravis.

Authors:  Sang-Jun Na; Seon-Hwa So; Kee Ook Lee; Young-Chul Choi
Journal:  J Neurol       Date:  2011-04-13       Impact factor: 4.849

Review 9.  IL-27: a double agent in the IL-6 family.

Authors:  G W Jones; D G Hill; A Cardus; S A Jones
Journal:  Clin Exp Immunol       Date:  2018-03-09       Impact factor: 4.330

10.  Lack of IL-6 during coxsackievirus infection heightens the early immune response resulting in increased severity of chronic autoimmune myocarditis.

Authors:  Maya C Poffenberger; Nadine Straka; Nahida El Warry; Dianne Fang; Iryna Shanina; Marc S Horwitz
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.